GLP-1s for Migraine and Intracranial Hypertension: What Early Evidence Shows

GLP-1 medications like semaglutide and tirzepatide are best known for weight loss and blood sugar control, but a small and growing body of research is looking at whether they help with headache disorders. The strongest signal so far is for idiopathic intracranial hypertension, a condition driven by high pressure inside the skull, where one randomized trial showed a GLP-1 drug lowered that pressure. Evidence for ordinary migraine is much thinner, mostly limited to one open-label pilot study and a few mixed safety reports, so it is far too early to call these drugs a migraine treatment.

The two conditions are not the same problem

Before looking at the evidence, it helps to separate two things that often get lumped together because both involve head pain.

Idiopathic intracranial hypertension (IIH) is a specific disease. Cerebrospinal fluid pressure inside the skull rises for reasons that are not fully understood. It mostly affects women of childbearing age who carry extra weight. The high pressure pushes on the optic nerves, which can cause swelling at the back of the eye (papilledema), vision loss, ringing in the ears that pulses with the heartbeat, and a daily pressure-type headache. Untreated, it can permanently damage sight. Weight loss is one of the few interventions proven to reduce both the pressure and the headaches, which is part of why GLP-1 drugs became interesting here.

Migraine is far more common and is a different beast. It is a neurological disorder with attacks of throbbing pain, often on one side, frequently with nausea, light sensitivity, and sometimes aura. Most people with migraine have completely normal intracranial pressure. There is overlap at the edges, though. Some researchers think problems with how the brain regulates pressure may play a role in certain stubborn, daily migraine cases, especially in people with obesity. That theory is the bridge that links the two research stories below.

The honest summary up front: the IIH evidence is early but real, anchored by an actual randomized trial. The migraine evidence is a hypothesis with one encouraging pilot study behind it. Keep that gap in mind through the rest of this article.

Why a diabetes and weight-loss drug would touch brain pressure

GLP-1 (glucagon-like peptide-1) receptor agonists copy a gut hormone. In the pancreas they boost insulin and curb glucagon. In the brain and stomach they slow digestion and reduce appetite, which drives weight loss. None of that obviously explains a drop in pressure inside the skull.

The link comes from a different tissue. The choroid plexus is the structure deep in the brain's ventricles that actually makes cerebrospinal fluid. Lab work in animals found that GLP-1 receptors sit on choroid plexus cells, and that switching them on slows down how fast that fluid is produced. Less fluid made means less pressure built up. This is a secretion-reduction mechanism, not a weight-loss mechanism.

That distinction turned out to matter in the human trial described below, because the pressure fell before meaningful weight came off. For migraine, the proposed mechanism is fuzzier. If a subset of treatment-resistant migraine is partly driven by subtle pressure dysregulation, then a drug that calms fluid production might help. That is a reasonable idea, but at this point it is a working theory, not a settled fact.

It is worth being clear about what this mechanism does and does not predict. A drug that lowers fluid production would be expected to help conditions where the core problem is too much pressure, which is exactly what IIH is. It would not obviously help the average migraine, where pressure is normal and the pain is generated by other pathways involving the trigeminal nerve and a signaling molecule called CGRP. That is why the most promising migraine preventives developed in the last decade target CGRP, not pressure. The pressure theory for migraine only makes sense for a narrow slice of patients, and even there it is unproven. Keeping the mechanism honest helps avoid the trap of assuming that because a drug helps one head-pain condition, it must help all of them.

What the IIH trial actually found

The cornerstone study is the IIH Pressure trial, a randomized, double-blind, placebo-controlled trial run in the United Kingdom and published in Brain in 2023 (Mitchell et al., PMID 36907221). It used the GLP-1 drug exenatide.

This trial had an unusual feature that makes its data hard to fake or fudge: participants had a tiny telemetric pressure sensor placed so that intracranial pressure could be measured directly and repeatedly, rather than estimated from a single lumbar puncture. That gives the numbers real weight despite the tiny sample.

It was small. Sixteen women were enrolled and fifteen completed, split into roughly seven on exenatide and eight on placebo. Everyone had active IIH with elevated pressure at the start.

Here is what the trial reported on its main outcome, intracranial pressure measured in centimeters of cerebrospinal fluid (cmCSF):

Time point	ICP change vs. placebo	P-value	Plain-language read
2.5 hours	−5.7 ± 2.9 cmCSF	0.048	Pressure dropped within hours
24 hours	−6.4 ± 2.9 cmCSF	0.030	Effect held at one day
12 weeks	−5.6 ± 3.0 cmCSF	0.058	Effect roughly held at 3 months

A few honest caveats about that table. This early-phase trial set its significance threshold (alpha) a priori at 0.1 rather than the conventional 0.05, so by the trial's own prespecified rule all three time points, including the 12-week result at p = 0.058, counted as statistically significant. Judged against the more familiar 0.05 cutoff, the 12-week result would not clear the bar, even though the earlier time points (p = 0.048 and p = 0.030) would. With only fifteen people, that is exactly the kind of borderline result you would expect, and it is why the authors and later reviewers call this a promising signal rather than proof.

The trial also looked at headache. The exenatide group reported about 7.7 fewer monthly headache days versus about 1.5 fewer on placebo. That looks meaningful, but the between-group difference was not statistically significant, so it should be read as supportive and exploratory, not as a proven headache benefit.

The most important mechanistic finding: there was no significant weight loss in the treatment arm at 12 weeks, yet the pressure still fell. That tells you the pressure drop was probably driven by reduced fluid production at the choroid plexus, not by slimming down. Side effects were the usual GLP-1 gastrointestinal complaints, with no serious safety alarms in this small group.

A separate analysis of the same trial population looked at thinking and memory and found no cognitive decline from using exenatide as a pressure-lowering agent (Grech et al., PMID 38212401). That is reassuring but, again, comes from a very small sample.

How strong is the IIH evidence overall

One small trial is not a foundation for routine treatment. To gauge the wider picture, two separate research teams pooled everything published. Both reviews landed in roughly the same place.

A systematic review in The Journal of Headache and Pain in 2025 collected the available studies on GLP-1 drugs in IIH (Ognard et al., PMID 41057780). A second systematic review in Headache gathered twelve reports, including three randomized trials, six retrospective cohorts, a case-control study, and case reports (de Oliveira et al., PMID 41246926).

The takeaways from these reviews were consistent and sober:

• GLP-1 use generally lined up with improvements in papilledema, headache burden, and body weight.
• Some cohorts reported patients needing less acetazolamide, the standard IIH medication.
• Direct pressure measurements and vision outcomes were mixed and inconsistent across studies.
• The overall certainty of evidence was rated low.
• Larger, standardized randomized trials are needed before this becomes standard care.

"Low-certainty evidence" is the key phrase. It means the direction looks favorable but the quality and size of the studies do not yet justify strong conclusions. For context, the current IIH consensus guidelines still center on weight management and acetazolamide as first-line approaches, with surgery reserved for vision-threatening cases (Mollan et al., 2018, PMID 29903905). GLP-1 drugs are not yet written into those guidelines as a recommended treatment.

A fair question is why the retrospective database studies looked more consistently positive than the prospectively followed patients. Database cohorts pull from large insurance or health-record datasets, which gives big numbers but weak control over confounding. People prescribed a GLP-1 drug differ from those who are not in ways that records cannot fully capture, and weight loss in those cohorts is hard to disentangle from any direct pressure effect. Prospective studies follow a defined group forward with planned measurements, which is more rigorous but smaller and messier in the real world. When the cleaner-but-smaller studies and the bigger-but-messier studies disagree, reviewers rightly hold back. That is the situation here, and it is the main reason both 2025 and 2026 reviews stopped short of recommending these drugs for IIH.

There is also a practical reason the evidence has not matured faster. IIH is relatively uncommon, the population most affected is narrow, and the gold-standard outcome, directly measured intracranial pressure, requires either repeated lumbar punctures or an implanted sensor. Both are invasive, which is why the one strong trial was so small. Bigger phase 3 trials in IIH are being planned and discussed, and those results, when they arrive, will matter far more than anything published so far.

What the migraine evidence actually says

This is where expectations need to come down. There is no randomized controlled trial of a GLP-1 drug for ordinary migraine. The headline studies you may have seen come from one research group.

The most-cited work is an open-label pilot study published in Headache in 2025 (Braca et al., PMID 40525593). Thirty-one adults who had both obesity and high-frequency or chronic migraine took the GLP-1 drug liraglutide as an add-on for twelve weeks. Monthly headache days fell from about 19.8 to about 10.7, a reduction of about 9.1 days (95% CI 5.41 to 12.84, p < 0.001).

That is a large drop, and it is statistically significant. But the study design caps how much you can read into it:

• No placebo group and no blinding. Open-label studies routinely overstate benefit because of the placebo effect and expectation bias. Migraine in particular responds strongly to placebo.
• Only 31 people, all with obesity, all already on other migraine treatment.
• The researchers deliberately excluded anyone with signs of IIH (papilledema, sixth nerve palsy, pulsatile tinnitus), trying to study migraine specifically.
• The authors themselves framed it as a hypothesis-generating pilot and called for a proper randomized, blinded trial with pressure measurement, which they are now planning.

So the correct read is: intriguing early signal in a specific, obese, treatment-resistant population, not evidence that GLP-1 drugs treat migraine in general.

There is also a flip side worth knowing. Headache is one of the more common reported side effects of GLP-1 drugs themselves. A pharmacovigilance analysis of the FDA Adverse Event Reporting System database found GLP-1 drugs were associated with disproportionately more reports of headache (ROR 1.74, 95% CI 1.65 to 1.84) and migraine (ROR 1.28, 95% CI 1.06 to 1.55) relative to all other drugs in the database (Eur Psychiatry, PMID 39901452). Reporting databases cannot prove cause and effect, and they are skewed by how heavily these drugs are used and discussed, but they are a reminder that for some people these medicines may trigger or worsen headaches rather than relieve them.

Putting the two evidence bases side by side

Question	IIH	Migraine (general)
Is there a randomized controlled trial?	Yes (small, n=15, exenatide)	No
Direction of effect	Lowers intracranial pressure; likely fewer headache days	One pilot suggests fewer headache days
Best available evidence quality	Low certainty, but anchored by an RCT	Very low; single open-label pilot
Proposed mechanism	Reduced CSF production at choroid plexus	Unclear; possible pressure link in obese subgroup
Could the drug also cause headaches?	Mild, transient early on	Yes, reported as a side effect in some users
Approved for this use?	No	No
Guideline-recommended?	No (guidelines favor weight loss + acetazolamide)	No

The pattern is clear. IIH has the stronger story because there is a real trial with directly measured pressure and a plausible mechanism. Migraine has a hopeful pilot and a logical hypothesis, nothing more.

How GLP-1s compare to standard options

For IIH, the established tools are weight loss, the medication acetazolamide (which itself reduces fluid production), and, for vision-threatening disease, surgical procedures like optic nerve sheath fenestration or shunting. The appeal of a GLP-1 drug is that it could lower pressure and drive weight loss at the same time, potentially attacking the condition from two directions. But acetazolamide has decades of use behind it and is far cheaper, while GLP-1 drugs are expensive, often not covered for this off-label use, and require injections in most current forms.

For migraine, the proven preventives are a different toolkit entirely: topiramate, beta-blockers, anti-CGRP monoclonal antibodies and gepants, and onabotulinumtoxinA for chronic migraine. These have large randomized trials behind them. A GLP-1 drug has none for migraine. If you have migraine and obesity, weight loss itself may modestly help migraine frequency, though in the liraglutide pilot the authors reported that headache improvement was statistically independent of weight change, since BMI barely moved over the study. For broader context on how GLP-1 effects differ across patient groups, see our GLP-1 by subgroup evidence guide.

One point raised by the pilot study's authors is worth highlighting in this comparison. Citing earlier preclinical work, they noted that GLP-1 drugs lowered intracranial pressure in animal models more strongly than drugs commonly used for IIH such as acetazolamide and topiramate, the latter a standard migraine and IIH medication that also reduces fluid production. Importantly, the pilot itself did not measure intracranial pressure in its patients, so this is an animal-model and mechanistic comparison, not a clinical head-to-head. If a GLP-1 advantage over topiramate ever holds up in a controlled human trial, it would be a genuine point of interest, since topiramate is poorly tolerated by many people because of side effects like tingling, word-finding trouble, and weight loss that some patients do not want. Until a blinded trial measures pressure directly and pits a GLP-1 drug against an established preventive in patients, this remains a hypothesis, not a reason to switch treatments.

It also helps to think about cost and burden. The proven migraine preventives range from inexpensive generic pills to pricey monthly injections, but all are approved and many are covered by insurance for migraine. A GLP-1 drug used off-label for headache would likely not be covered for that purpose, would cost hundreds of dollars a month out of pocket in many cases, and would carry its own side effect load. That math matters when the headache benefit is still unproven.

Safety: what to weigh

The safety profile of GLP-1 drugs in these neurological studies matched what is already well documented. The most common issues were gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually worst when starting or increasing the dose. For a fuller picture of the general side effect profile, see our complete GLP-1 side effects guide.

A few points specific to the head and eyes deserve attention here:

• Eyes and the optic nerve. IIH is fundamentally a vision-threatening disease, so anyone using a GLP-1 drug in this setting needs ongoing eye monitoring by a specialist, not self-management. Separately, there has been debate about whether semaglutide is linked to a rare optic nerve stroke called NAION. We cover that question in detail in our review of the GLP-1 and NAION blindness risk evidence, and the related coverage of the Wegovy blindness risk study. The bottom line: the absolute risk appears low and the data are still being sorted out, but it is a reason for caution in anyone with existing eye disease.
• Headache as a side effect. As noted, some users report new or worse headaches, especially in the first weeks. If your headaches clearly worsen after starting, that is worth telling your prescriber.
• The usual GLP-1 warnings still apply. These include the boxed warning about thyroid C-cell tumors seen in rodents, pancreatitis reports, and gallbladder problems. Anyone considering these drugs should review the FDA-approved labeling, available through Drugs@FDA.

None of the neurological trials were large or long enough to detect rare harms on their own. That is another reason to treat off-label use for headache disorders cautiously.

Who might this matter for

Based on the current evidence, here is a realistic read on who this research touches today.

People with confirmed IIH and obesity are the group with the most relevant evidence. Even so, a GLP-1 drug is not an approved or guideline-backed IIH treatment, so it would only be considered off-label, under the care of a neurologist and ophthalmologist, usually after or alongside standard options. The active research pipeline means this picture could change in the next few years.

People with treatment-resistant migraine and obesity are the population in the one migraine pilot. If your migraine has not responded to proven preventives and you also need to lose significant weight, a GLP-1 drug might be discussed, but for the weight indication, with any migraine benefit treated as an unproven bonus rather than the goal.

People with typical, well-controlled-weight migraine have essentially no evidence supporting GLP-1 drugs for their headaches, and the proven migraine preventives are the right path.

Anyone with existing eye disease should be extra cautious given the open questions around the optic nerve.

The single most important takeaway: do not start, stop, or switch any medication based on early-stage research. These drugs are prescription medicines with real risks, and the headache evidence is still being built.

Frequently Asked Questions

Can Ozempic or Wegovy cure my migraines?

No. There is no completed randomized controlled trial showing that semaglutide (Ozempic, Wegovy) treats migraine. The one supportive migraine study used a different GLP-1 drug, liraglutide, was open-label, and enrolled only 31 people who all had obesity. It is a preliminary signal, not proof, and these drugs are not approved or recommended for migraine.

Is the IIH evidence strong enough to ask my doctor for a GLP-1 drug?

The IIH evidence is the strongest in this area because it includes a small randomized trial with directly measured intracranial pressure, but systematic reviews still rate the overall evidence as low certainty. Current consensus guidelines center on weight loss and acetazolamide. A GLP-1 drug for IIH would be an off-label decision made with a neurologist and eye specialist, not a routine first choice.

How would a weight-loss drug lower pressure inside the skull?

GLP-1 receptors exist on the choroid plexus, the brain tissue that produces cerebrospinal fluid. Activating them appears to slow fluid production, which can lower intracranial pressure. In the exenatide trial, pressure fell even without significant weight loss, suggesting the effect came from reduced fluid production rather than from slimming down.

Could a GLP-1 drug actually make my headaches worse?

It can for some people. Headache is a commonly reported side effect, especially in the first weeks of treatment, and a pharmacovigilance analysis found GLP-1 drugs were associated with disproportionately more headache and migraine reports than other drugs in the FDA reporting database. Reporting data cannot prove cause and effect, but if your headaches clearly worsen after starting, tell your prescriber.

What treatments have better evidence for these conditions right now?

For IIH, weight management and acetazolamide are first-line, with surgery for vision-threatening cases. For migraine prevention, the well-studied options include topiramate, beta-blockers, anti-CGRP antibodies and gepants, and onabotulinumtoxinA for chronic migraine. All of these have large randomized trials behind them, which GLP-1 drugs do not yet have for either condition.

This article is for general information only and is not medical advice. Talk to a qualified healthcare professional before starting, stopping, or changing any medication.